LXRX (Lexicon Pharmaceuticals) Common Stock: $0.43 Mil (As of Mar. 2026)


LXRX Lexicon Pharmaceuticals Inc LXRX
57 GF Score
Price $2.18
GF Value $8.39
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Lexicon Pharmaceuticals Common Stock?

Lexicon Pharmaceuticals LXRX -2.47% 57 Common Stock is $0.43 Mil as of Mar. 2026. GuruFocus rates LXRX with a GF Score™ of 57/100 and a GF Value™ of $8.39 (Possible Value Trap). The stock has 3 warning signs investors should review.

Lexicon Pharmaceuticals's quarterly common stock stayed the same from Sep. 2025 ($0.37 Mil) to Dec. 2025 ($0.37 Mil) but then increased from Dec. 2025 ($0.37 Mil) to Mar. 2026 ($0.43 Mil).

Lexicon Pharmaceuticals's annual common stock increased from Dec. 2023 ($0.25 Mil) to Dec. 2024 ($0.36 Mil) and increased from Dec. 2024 ($0.36 Mil) to Dec. 2025 ($0.37 Mil).

Lexicon Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Lexicon Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexicon Pharmaceuticals Common Stock Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.19 0.25 0.36 0.37

Lexicon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.37 0.37 0.37 0.43
LXRX
57GF Score
Lexicon Pharmaceuticals Inc LXRX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexicon Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.43 Mil mean?
Lexicon Pharmaceuticals (LXRX) has a Common Stock of $0.43 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Lexicon Pharmaceuticals and its competitors.
Is Lexicon Pharmaceuticals' Common Stock too high?
Lexicon Pharmaceuticals' current Common Stock is $0.43 Mil. Overall, Lexicon Pharmaceuticals has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lexicon Pharmaceuticals' Common Stock compare to CGEM and WVE?
Lexicon Pharmaceuticals' Common Stock of $0.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Lexicon Pharmaceuticals and its competitors. Lexicon Pharmaceuticals's current Common Stock is $0.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexicon Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lexicon Pharmaceuticals (LXRX) is currently considered Possible Value Trap. The stock's GF Value™ is $8.39, compared to a current price of $2.18 — trading 74.1% below its estimated fair value. The current Common Stock is $0.43 Mil. Lexicon Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Lexicon Pharmaceuticals (LXRX), the current Common Stock is $0.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexicon Pharmaceuticals (LXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexicon Pharmaceuticals stock appears to be undervalued. The current stock price of $2.18 is trading 74.1% below its estimated GF Value™ of $8.39. GuruFocus considers Lexicon Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LXRX:

  • Common Stock: $0.43 Mil
  • GF Value™: $8.39 vs. price of $2.18 (74.1% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the LXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexicon Pharmaceuticals Business Description

Address 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
57GF Score

Get the complete analysis for LXRX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.18
Price
$8.39
GF Value